Addictovigilance Centre, Lapeyronie Hospital, CHU de Montpellier, Univ Montpellier, 34000 Montpellier, France.
Addictovigilance Centre, Medecine Faculty, CHU, 31000 Toulouse, France.
Therapie. 2023 Nov-Dec;78(6):647-657. doi: 10.1016/j.therap.2023.02.002. Epub 2023 Feb 15.
Alprazolam, a high-potency and short-acting anxiolytic benzodiazepine, is one of the most misused benzodiazepines in France. In the context of various reports on alprazolam misuse during the COVID-19 pandemic, the objective of this study was to assess alprazolam abuse potential by analyzing French addictovigilance and international data.
Data collected from 2011 to 2020 using the following epidemiological tools of the French Addictovigilance Network were analyzed: spontaneous reports (SRs), OPPIDUM (addiction care center data), OSIAP (falsified prescriptions), DRAMES (substance-related deaths), and chemical submission surveys. Moreover, the VigiBase™ database was analyzed to evaluate alprazolam abuse liability worldwide.
During the study period, 675 SRs concerning alprazolam misuse were recorded (sex ratio: ̴1; median age: 39 years). The desired effects were intensification of the therapeutic anxiolytic effect, euphoric effect, and management of substance withdrawal. Alprazolam was the third and first benzodiazepine listed in OPPIDUM and OSIAP surveys. Analysis of the SR and OPPIDUM data showed a recent increase in the alprazolam-opioid combination. In DRAMES data, alprazolam was directly linked to 11 deaths (associated with opioids in 10/11). VigiBase™ data analysis highlighted that France was the third country with the most cases of alprazolam misuse. The disproportionality analysis showed that in France, alprazolam was associated with higher risk of misuse and dependence compared with other benzodiazepines: reporting odds ratio=1.43, (95% CI: 1.04-1.95) and=1.97 (95% CI:1.50-2.59), respectively.
This study highlighted an increase in various signals of alprazolam abuse in France, and an increased use of the alprazolam-opioid combination that was also linked to most of the recorded alprazolam-linked deaths. These signals have been reported also in the international literature, and should be thoroughly investigated.
阿普唑仑是一种高效、短效的苯二氮䓬类抗焦虑药物,是法国最易被滥用的苯二氮䓬类药物之一。在 COVID-19 大流行期间有关阿普唑仑滥用的各种报告背景下,本研究旨在通过分析法国和国际药物警戒数据评估阿普唑仑的滥用潜力。
使用法国药物警戒网络的以下流行病学工具收集 2011 年至 2020 年的数据进行分析:自发报告(SRs)、OPPIDUM(成瘾治疗中心数据)、OSIAP(伪造处方)、DRAMES(药物相关死亡)和化学物质提交调查。此外,还分析了 VigiBase™ 数据库以评估全球范围内阿普唑仑的滥用可能性。
研究期间共记录了 675 例阿普唑仑滥用的 SR(性别比:~1;中位年龄:39 岁)。期望的效果是增强治疗性抗焦虑作用、欣快作用和管理物质戒断。阿普唑仑在 OPPIDUM 和 OSIAP 调查中分别位列第三和第一的苯二氮䓬类药物。对 SR 和 OPPIDUM 数据的分析显示,阿普唑仑-阿片类药物联合用药近期有所增加。在 DRAMES 数据中,阿普唑仑与 11 例死亡直接相关(10/11 例与阿片类药物相关)。VigiBase™ 数据分析显示,法国是报告阿普唑仑滥用病例第三多的国家。比例失衡分析表明,与其他苯二氮䓬类药物相比,法国阿普唑仑与更高的滥用和依赖风险相关:报告比值比=1.43(95%CI:1.04-1.95)和=1.97(95%CI:1.50-2.59)。
本研究强调了法国阿普唑仑滥用的各种信号增加,以及阿普唑仑-阿片类药物联合用药的使用增加,该联合用药也与记录的大多数阿普唑仑相关死亡有关。这些信号也在国际文献中报道过,应进行彻底调查。